In a report released today, Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Enanta Pharmaceuticals, with a price target of $20.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Brandon Folkes’s rating is based on the promising results from Enanta Pharmaceuticals’ Phase 2b trial of zelicapavir for RSV in high-risk adults. Although the primary endpoint was missed, the trial showed strong outcomes in the HR3 population and all RSV symptoms, suggesting a high likelihood of approval for zelicapavir as an RSV therapeutic. The trial’s data indicates a significant potential upside for ENTA’s market value, as there are currently no approved RSV therapeutics.
Furthermore, the trial demonstrated a faster resolution of RSV symptoms compared to existing treatments, with notable improvements in patient outcomes and reduced hospitalization rates. The compelling virologic data, including faster viral clearance and a greater decline in viral load, supports the mechanism of action of zelicapavir, reinforcing the positive outlook for its approval. These factors collectively underpin the Buy rating and the $20 price target set by Brandon Folkes.
Folkes covers the Healthcare sector, focusing on stocks such as Eupraxia Pharmaceuticals, MannKind, and Omeros. According to TipRanks, Folkes has an average return of -4.7% and a 38.51% success rate on recommended stocks.
In another report released on September 15, Evercore ISI also maintained a Buy rating on the stock with a $12.00 price target.